Our website uses cookies which are small bits of data stored as text files on your device. We use these cookies as described in our cookie policy. You can disable or change your cookie settings at any time but parts of our site will not function correctly without them.

IncyteCARES for Jakafi is a program for residents
of the United States and Puerto Rico.

Education and Support for
Jakafi® (ruxolitinib)

Graphic of a female patient talking to male doctor holding a clipboard Graphic of a female patient talking to male doctor holding a clipboard Graphic of a female patient talking to male doctor holding a clipboard

A key part of the IncyteCARES for Jakafi program is the helpful information we can provide for eligible patients and caregivers. Through our call center, we can answer questions about your condition, what you might experience during your treatment, and how to properly take Jakafi.

When you’re first prescribed Jakafi, you’ll also receive a Welcome Kit including:

  • Education about your condition
  • Information about Jakafi and research that supported its approval
  • An information card to share with your traditional pharmacy (so they’re aware of your Jakafi prescription)
  • Details about the IncyteCARES for Jakafi program and how to contact us

An IncyteCARES for Jakafi representative calls all newly enrolled patients to answer questions and see how else they can help. Depending on your underlying condition, we may also offer an ongoing series of educational mailings and occasional follow-up calls.

Resources for Help Managing Day to Day

IncyteCARES for Jakafi can also connect eligible patients to resources that can help with managing your condition, having better conversations with your Healthcare Professional, and maintaining a positive outlook.

These may include:

  • Tools for tracking your symptoms and daily medicines
  • Help with finding patient or caregiver support groups
  • Sources that provide emotional, financial, and other counseling services at low or no cost
  • Information about organizations that may offer eligible patients help with transportation to medical appointments, treatment-related costs, and more

Helpful Support for You

Image of Rob—Click to view the video to learn why he appreciates IncyteCARES for Jakafi

Discover why Rob appreciates IncyteCARES for Jakafi.

Image of Sue—Click to view the video about how IncyteCARES for Jakafi supports people who take Jakafi (ruxolitinib)

Meet Sue and see how IncyteCARES for Jakafi supports people taking Jakafi® (ruxolitinib).

video Image of Dan—Click to view the video about how IncyteCARES for Jakafi has helped patients like him

See how IncyteCARES for Jakafi has helped patients like Dan.

Image of video - Positive Steps for Staying on Therapy With Jakafi® (ruxolitinib)—Click to watch

Learn about the healthy foods and exercise your body needs in this video.

Image of an arrow pointing to a desktop computer

Find Other Resources and Support at Jakafi.com

“The support I get from IncyteCARES for Jakafi helped me keep trying when I wanted to give up. It has been a wonderful program for me.” – Billy R.

phone support icon

Need Help?

Our IncyteCARES for Jakafi team is available
Monday through Friday, 8 am–8 pm ET

Call us at 1-855-452-5234

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Jakafi is used to treat adults and children 12 years of age and older with chronic graft-versus-host disease (GVHD) who have taken one or two types of treatments and they did not work well enough.

IMPORTANT SAFETY INFORMATION

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, or white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.